Back to Business

AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial

Business July 27, 2026 at 6:40 AM

AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial

Investing.com

Read at Investing.com

More Stories

Piper Sandler initiates Williams-Sonoma stock with overweight rating

Piper Sandler initiates Williams-Sonoma stock with overweight rating

🇺🇸 Investing.com 20m ago

Stifel initiates ITG stock with buy rating on fiber growth

Stifel initiates ITG stock with buy rating on fiber growth

🇺🇸 Investing.com 20m ago

Piper Sandler cuts Stellantis stock rating on margin concerns

Piper Sandler cuts Stellantis stock rating on margin concerns

🇺🇸 Investing.com 20m ago

Your world briefing, in your pocket

AI-curated news from 12 countries and 10 languages — coming soon on iOS and Android.

Coming soon on App Store Coming soon on Google Play